These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 25829323)

  • 1. Iron supplementation associates with low mortality in pre-dialyzed advanced chronic kidney disease patients receiving erythropoiesis-stimulating agents: a nationwide database analysis.
    Kuo KL; Hung SC; Liu JS; Chang YK; Hsu CC; Tarng DC
    Nephrol Dial Transplant; 2015 Sep; 30(9):1518-25. PubMed ID: 25829323
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Add-on Protective Effect of Pentoxifylline in Advanced Chronic Kidney Disease Treated with Renin-Angiotensin-Aldosterone System Blockade - A Nationwide Database Analysis.
    Kuo KL; Hung SC; Liu JS; Chang YK; Hsu CC; Tarng DC
    Sci Rep; 2015 Nov; 5():17150. PubMed ID: 26612282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
    Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
    Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Iron supplementation in the non-dialysis chronic kidney disease (ND-CKD) patient: oral or intravenous?
    Macdougall IC
    Curr Med Res Opin; 2010 Feb; 26(2):473-82. PubMed ID: 20014980
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of spironolactone on the risks of mortality and hospitalization for heart failure in pre-dialysis advanced chronic kidney disease: A nationwide population-based study.
    Tseng WC; Liu JS; Hung SC; Kuo KL; Chen YH; Tarng DC; Hsu CC
    Int J Cardiol; 2017 Jul; 238():72-78. PubMed ID: 28363684
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thiazolidinediones and Risk of Long-Term Dialysis in Diabetic Patients with Advanced Chronic Kidney Disease: A Nationwide Cohort Study.
    Chen YH; Chiang MH; Liu JS; Chang YK; Kuo KL; Hung SC; Tai HL; Hsu CC; Tarng DC
    PLoS One; 2015; 10(6):e0129922. PubMed ID: 26083376
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trends in anemia care in non-dialysis-dependent chronic kidney disease (CKD) patients in the United States (2006-2015).
    Park H; Liu X; Henry L; Harman J; Ross EA
    BMC Nephrol; 2018 Nov; 19(1):318. PubMed ID: 30413150
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-Term Effects of Ketoanalogues on Mortality and Renal Outcomes in Advanced Chronic Kidney Disease Patients Receiving a Low-Protein Diet.
    Wang YC; Juan SH; Chou CL; Hsieh TC; Wu JL; Fang TC
    Nutrients; 2020 Sep; 12(9):. PubMed ID: 32899821
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and economic outcomes in Medicare beneficiaries with stage 3 or stage 4 chronic kidney disease and anemia: the role of intravenous iron therapy.
    Knight TG; Ryan K; Schaefer CP; D'Sylva L; Durden ED
    J Manag Care Pharm; 2010 Oct; 16(8):605-15. PubMed ID: 20866165
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renoprotective effect of renin-angiotensin-aldosterone system blockade in patients with predialysis advanced chronic kidney disease, hypertension, and anemia.
    Hsu TW; Liu JS; Hung SC; Kuo KL; Chang YK; Chen YC; Hsu CC; Tarng DC
    JAMA Intern Med; 2014 Mar; 174(3):347-54. PubMed ID: 24343093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ketoanalogue supplements reduce mortality in patients with pre-dialysis advanced diabetic kidney disease: A nationwide population-based study.
    Chen HY; Sun CY; Lee CC; Wu IW; Chen YC; Lin YH; Fang WC; Pan HC
    Clin Nutr; 2021 Jun; 40(6):4149-4160. PubMed ID: 33597108
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dipyridamole decreases dialysis risk and improves survival in patients with pre-dialysis advanced chronic kidney disease.
    Kuo KL; Hung SC; Tseng WC; Liu JS; Lin MH; Hsu CC; Tarng DC
    Oncotarget; 2018 Jan; 9(4):5368-5377. PubMed ID: 29435184
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anaemia management and mortality risk in newly visiting patients with chronic kidney disease in Japan: The CKD-ROUTE study.
    Iimori S; Naito S; Noda Y; Nishida H; Kihira H; Yui N; Okado T; Sasaki S; Uchida S; Rai T
    Nephrology (Carlton); 2015 Sep; 20(9):601-8. PubMed ID: 25917812
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes in patients with chronic kidney disease not on dialysis receiving extended dosing regimens of darbepoetin alfa: long-term results of the EXTEND observational cohort study.
    Galle JC; Addison J; Suranyi MG; Claes K; Di Giulio S; Guerin A; Herlitz H; Kiss I; Farouk M; Manamley N; Wirnsberger G; Winearls C
    Nephrol Dial Transplant; 2016 Dec; 31(12):2073-2085. PubMed ID: 27190334
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Switching patients with non-dialysis chronic kidney disease from oral iron to intravenous ferric carboxymaltose: effects on erythropoiesis-stimulating agent requirements, costs, hemoglobin and iron status.
    Toblli JE; Di Gennaro F
    PLoS One; 2015; 10(4):e0125528. PubMed ID: 25928811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anaemia management in patients with chronic kidney disease: Taiwan practice guidelines.
    Hung SC; Kuo KL; Tarng DC; Hsu CC; Wu MS; Huang TP
    Nephrology (Carlton); 2014 Dec; 19(12):735-9. PubMed ID: 25156587
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Types of erythropoiesis-stimulating agents and risk of end-stage kidney disease and death in patients with non-dialysis chronic kidney disease.
    Minutolo R; Garofalo C; Chiodini P; Aucella F; Del Vecchio L; Locatelli F; Scaglione F; De Nicola L
    Nephrol Dial Transplant; 2021 Jan; 36(2):267-274. PubMed ID: 32829405
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative Effectiveness of Iron and Erythropoiesis-Stimulating Agent Dosing on Health-Related Quality of Life in Patients Receiving Hemodialysis.
    Freburger JK; Ellis AR; Wang L; Butler AM; Kshirsagar AV; Winkelmayer WC; Brookhart MA
    Am J Kidney Dis; 2016 Feb; 67(2):271-82. PubMed ID: 26508682
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of erythropoiesis-stimulating agents on healthcare utilization, costs, and outcomes in chronic kidney disease.
    Maddux FW; Shetty S; del Aguila MA; Nelson MA; Murray BM
    Ann Pharmacother; 2007 Nov; 41(11):1761-9. PubMed ID: 17895328
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Iron repletion is associated with reduction in platelet counts in non-dialysis chronic kidney disease patients independent of erythropoiesis-stimulating agent use: a retrospective cohort study.
    Yessayan L; Yee J; Zasuwa G; Frinak S; Besarab A
    BMC Nephrol; 2014 Jul; 15():119. PubMed ID: 25038614
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.